NASDAQ: NRXP

NRx Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for NRXP. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (vendor)$-1.34

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 20:50 UTC.

What NRx Pharmaceuticals, Inc. does

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel treatments for central nervous system disorders including depression, chronic pain, PTSD, and schizophrenia, with a focus on drugs that enhance neuroplasticity by modulating the NMDA receptor. The company's lead drug candidates are KETAFREE (a preservative-free ketamine formulation), NRX-100 (an intravenous ketamine formulation), and NRX-101 (an oral combination of D-cycloserine and lurasidone), all in various stages of FDA submission.

Summarized from NRx Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-06-04
EPS (vendor)	$-1.34

Charts

Charts are in the appInteractive charts for NRXP are available in Oxford Ledge.
Open NRXP in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity

Source: SEC EDGAR · Filed 2026-02-17

Most recent filed transactions — February 2026:

2026-02-17Chief Operating OfficerStock Option (right to buy)Award100,000—
2025-09-10DirectorStock Option (right to buy)Award25,000—
2025-09-10DirectorStock Option (right to buy)Award50,000—

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

B Group, Inc.4,091,767$16.74M+36.4%
VANGUARD CAPITAL MANAGEMENT LLC1,618,159$6.62M+39.5%
AMERIPRISE FINANCIAL INC928,728$3.80MNEW

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-11-20Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-10-11Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-08-20Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does NRx Pharmaceuticals, Inc. do?

When did NRXP last file with the SEC?

NRx Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-04. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 20:50 UTC. This page is also available as JSON at /api/data?ticker=NRXP and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NRXP and 5,000+ tickers.

Create a free account — keep NRXP

For your agent

GET /api/data?ticker=NRXP

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt